TY  - JOUR
A1  - Hopfner, Franziska
A1  - Müller, Stefanie H.
A1  - Steppat, Dagmar
A1  - Miller, Joanna
A1  - Schmidt, Nele
A1  - Wandinger, Klaus-Peter
A1  - Leypoldt, Frank
A1  - Berg, Daniela
A1  - Franke, Andre
A1  - Lieb, Wolfgang
A1  - Tittmann, Lukas
A1  - Balzer-Geldsetzer, Monika
A1  - Baudrexel, Simon
A1  - Dodel, Richard
A1  - Hilker-Roggendorf, Rüdiger
A1  - Kalbe, Elke
A1  - Kassubek, Jan
A1  - Klockgether, Thomas
A1  - Liepelt-Scarfone, Inga
A1  - Mollenhauer, Brit
A1  - Neuser, Petra
A1  - Reetz, Kathrin
A1  - Riedel, Oliver
A1  - Schulte, Claudia
A1  - Schulz, Jörg B.
A1  - Spottke, Annika
A1  - Storch, Alexander
A1  - Trenkwalder, Claudia
A1  - Wittchen, Hans-Ulrich
A1  - Witt, Karsten
A1  - Wüllner, Ullrich
A1  - Deuschl, Günther
A1  - Kuhlenbäumer, Gregor
T1  - No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors
T2  - Translational neurodegeneration
N2  - Background: IgG-class autoantibodies to N-Methyl-D-Aspartate (NMDA)-type glutamate receptors define a novel entity of autoimmune encephalitis. Studies examining the prevalence of NMDA IgA/IgM antibodies in patients with Parkinson disease with/without dementia produced conflicting results. We measured NMDA antibodies in a large, well phenotyped sample of Parkinson patients without and with cognitive impairment (n = 296) and controls (n = 295) free of neuropsychiatric disease. Detailed phenotyping and large numbers allowed statistically meaningful correlation of antibody status with diagnostic subgroups as well as quantitative indicators of disease severity and cognitive impairment.
Methods: NMDA antibodies were analysed in the serum of patients and controls using well established validated assays. We used anti-NMDA antibody positivity as the main independent variable and correlated it with disease status and phenotypic characteristics.
Results: The frequency of NMDA IgA/IgM antibodies was lower in Parkinson patients (13%) than in controls (22%) and higher than in previous studies in both groups. NMDA IgA/IgM antibodies were neither significantly associated with diagnostic subclasses of Parkinson disease according to cognitive impairment, nor with quantitative indicators of disease severity and cognitive impairment. A positive NMDA antibody status was positively correlated with age in controls but not in Parkinson patients.
Conclusion: It is unlikely albeit not impossible that NMDA antibodies play a significant role in the pathogenesis or progression of Parkinson disease e.g. to Parkinson disease with dementia, while NMDA IgG antibodies define a separate disease of its own.
KW  - NMDA antibody
KW  - NMDA IgA/IgM antibodies
KW  - Parkinson disease
KW  - Cognitive impairment
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/50249
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-502492
SN  - 2047-9158
N1  - Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
VL  - 8
IS  - Art. 11
SP  - 1
EP  - 7
PB  - Biomed Central
CY  - London
ER  -